Regeneron's US macular edema win barely noticed by investors
This article was originally published in Scrip
Executive Summary
As expected, the US FDA gave the nod to Regeneron Pharmaceuticals to market Eylea (aflibercept) as a treatment of macular edema following central retinal vein occlusion (CRVO) at the recommended dosage of 2 mg every four weeks.